ATE312089T1 - Vitronektin rezeptor antagonisten - Google Patents

Vitronektin rezeptor antagonisten

Info

Publication number
ATE312089T1
ATE312089T1 AT97909979T AT97909979T ATE312089T1 AT E312089 T1 ATE312089 T1 AT E312089T1 AT 97909979 T AT97909979 T AT 97909979T AT 97909979 T AT97909979 T AT 97909979T AT E312089 T1 ATE312089 T1 AT E312089T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
AT97909979T
Other languages
English (en)
Inventor
James Francis Callahan
Russell Donovan Cousins
Richard Mccullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE312089T1 publication Critical patent/ATE312089T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97909979T 1996-10-02 1997-10-01 Vitronektin rezeptor antagonisten ATE312089T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE312089T1 true ATE312089T1 (de) 2005-12-15

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909979T ATE312089T1 (de) 1996-10-02 1997-10-01 Vitronektin rezeptor antagonisten

Country Status (36)

Country Link
EP (1) EP0957917B1 (de)
JP (2) JP4491072B2 (de)
KR (1) KR100589578B1 (de)
CN (1) CN1114403C (de)
AP (1) AP1463A (de)
AR (1) AR008878A1 (de)
AT (1) ATE312089T1 (de)
AU (1) AU733417B2 (de)
BG (1) BG64581B1 (de)
BR (1) BR9712248B1 (de)
CA (1) CA2267224C (de)
CO (1) CO4900046A1 (de)
CY (1) CY2576B1 (de)
CZ (1) CZ299076B6 (de)
DE (1) DE69734833T2 (de)
DK (1) DK0957917T3 (de)
DZ (1) DZ2320A1 (de)
EA (1) EA002419B1 (de)
ES (1) ES2252775T3 (de)
HU (1) HU229221B1 (de)
ID (1) ID19623A (de)
IL (1) IL129243A (de)
MA (1) MA24361A1 (de)
MY (1) MY137606A (de)
NO (1) NO320194B1 (de)
NZ (1) NZ334953A (de)
PE (1) PE10499A1 (de)
PL (1) PL190859B1 (de)
RO (1) RO119881B1 (de)
SA (1) SA98180936B1 (de)
SK (1) SK285029B6 (de)
TR (1) TR199900737T2 (de)
TW (1) TW487702B (de)
UA (1) UA60311C2 (de)
UY (2) UY24735A1 (de)
WO (1) WO1998014192A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
BR9813214A (pt) * 1997-09-24 2000-08-29 Smithkline Beecham Corp Antagonista de receptor vitronectina
CN1273529A (zh) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
CA2356929A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
AU747503B2 (en) * 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
IL146222A0 (en) * 1999-04-30 2002-07-25 Univ Michigan Therapeutic applications of pro-apoptotic benzodiazepines
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
AU2002305164B2 (en) * 2001-04-10 2005-07-28 Smithkline Beecham Corporation Method of inhibiting adhesion formation
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
EP1387688A2 (de) * 2001-05-03 2004-02-11 Merck & Co., Inc. Benzazepinon-alpha-v-integrin-rezeptorantagonisten
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
JP2006522139A (ja) * 2003-04-04 2006-09-28 スミスクライン・ビーチャム・コーポレイション ベンズアゼピンの製造方法およびその中間体
HRP20130782T1 (en) * 2004-04-02 2013-09-30 The Regents Of The University Of California, Office Of Technology Transfer Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
JP5637855B2 (ja) 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
CA2705916C (en) * 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
WO2009111679A2 (en) * 2008-03-06 2009-09-11 Smithkline Beecham Corporation Process
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
EP2415474B1 (de) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmazeutische zusammensetzung zur behandlung und prävention von augenleiden
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
CN102753179A (zh) 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
EP2325194A1 (de) * 2009-11-24 2011-05-25 Glycotope GmbH Verfahren zur Reinigung von Glykoproteinen
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
BR112022021228A2 (pt) * 2020-04-26 2022-12-06 Jiangsu Nhwa Pharmaceutical Co Ltd Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ259802A (en) * 1992-12-21 1997-10-24 Smithkline Beecham Corp Bicyclic derivatives and pharmaceutical compositions
EP0762882A4 (de) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin-rezeptor-antagonisten
JPH10504808A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
EP0777657A1 (de) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclische verbindungen
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
BG103299A (en) 2000-01-31
CZ113299A3 (cs) 2000-03-15
KR100589578B1 (ko) 2006-06-15
DE69734833T2 (de) 2006-07-13
UA60311C2 (uk) 2003-10-15
KR20000048816A (ko) 2000-07-25
BR9712248B1 (pt) 2010-06-29
AU733417B2 (en) 2001-05-17
NO991590L (no) 1999-05-31
DK0957917T3 (da) 2006-04-18
BR9712248A (pt) 1999-08-24
CN1238689A (zh) 1999-12-15
AU4746297A (en) 1998-04-24
CO4900046A1 (es) 2000-03-27
AP1463A (en) 2005-09-10
HUP9903769A2 (hu) 2000-03-28
JP2001501936A (ja) 2001-02-13
CY2576B1 (en) 2008-07-02
AP9901493A0 (en) 1999-03-31
EA002419B1 (ru) 2002-04-25
HUP9903769A3 (en) 2000-07-28
CZ299076B6 (cs) 2008-04-16
NO320194B1 (no) 2005-11-14
PL332674A1 (en) 1999-09-27
SA98180936B1 (ar) 2006-05-30
SK42599A3 (en) 1999-12-10
RO119881B1 (ro) 2005-05-30
NO991590D0 (no) 1999-03-31
MY137606A (en) 2009-02-27
AR008878A1 (es) 2000-02-23
WO1998014192A1 (en) 1998-04-09
MA24361A1 (fr) 1998-07-01
EP0957917A4 (de) 2002-05-15
ID19623A (id) 1998-07-23
HK1023730A1 (en) 2000-09-22
NZ334953A (en) 2000-01-28
IL129243A (en) 2004-07-25
UY24735A1 (es) 1998-03-30
JP4491072B2 (ja) 2010-06-30
DZ2320A1 (fr) 2002-12-28
CA2267224A1 (en) 1998-04-09
TR199900737T2 (xx) 1999-07-21
IL129243A0 (en) 2000-02-17
HU229221B1 (en) 2013-09-30
CA2267224C (en) 2007-03-13
ES2252775T3 (es) 2006-05-16
CN1114403C (zh) 2003-07-16
DE69734833D1 (de) 2006-01-12
SK285029B6 (sk) 2006-04-06
JP2010006838A (ja) 2010-01-14
EA199900356A1 (ru) 2000-02-28
EP0957917B1 (de) 2005-12-07
PL190859B1 (pl) 2006-02-28
UY24935A1 (es) 2001-07-31
PE10499A1 (es) 1999-03-27
BG64581B1 (bg) 2005-08-31
EP0957917A1 (de) 1999-11-24
TW487702B (en) 2002-05-21

Similar Documents

Publication Publication Date Title
ATE312089T1 (de) Vitronektin rezeptor antagonisten
NO965608D0 (no) Vitronectin-reseptor-antagonister
BR9612381A (pt) Antagonistas receptores vitronectina
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
NO986110D0 (no) IL-8 reseptor-antagonister
NO986109D0 (no) IL-8 reseptor-antagonister
ATE315035T1 (de) Ccr-3-rezeptor-antagonisten
NO990668D0 (no) IL-8 reseptor antagonister
EP0885205A4 (de) Fibrinogen-rezeptor-antagonisten
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
DE69920518D1 (de) Vitronectin rezeptor antagonist
NO20010620D0 (no) Vitronektinreseptor-antagonister
EP0957908A4 (de) Antagonisten des fibrinogen rezeptors
SI0957917T1 (sl) Antagonisti receptorja vitronektina
DE69830671D1 (de) Integrin-rezeptor-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0957917

Country of ref document: EP